REG - IXICO plc - Contract Win

IXICOAnnouncement

10/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230310:nRSJ5037Sa&default-theme=true

RNS Number : 5037S  IXICO plc  10 March 2023

 

10 March 2023

 

IXICO plc

("IXICO" or the "Company")

 

Contract win for a Phase 1/2 rare neurodegenerative disease gene therapy
study; value c.£0.7m.

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent
insights in neuroscience, announces that it has been selected by a biotech
company and new client, to provide MRI imaging services for patient selection
and efficacy analysis in patients with a rare form of dementia. The trial
deploys an innovative gene therapy approach and is expected to last for just
over four years.

 

Since its inception, IXICO has built an extensive portfolio of proprietary
imaging data management and analysis technologies for the investigation of
neurological disorders across the entire drug development lifecycle, from
phase I through to commercialisation. IXICO's recently launched IXIQ.Ai
platform enables the measurement of brain volumetry with increased
sensitivity, compared to widely used tools.

 

 

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be awarded this
contract to support the development of this promising treatment in a rare
neurodegenerative disease. It is great to see our IXIQ.Ai advanced analytics
technology being chosen by new clients to support patient eligibility
assessment in innovative trial designs. Deploying such approaches enables
individual dosing decisions, paving the way towards personalised medicine."

 

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900
 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough machine learning AI data
analytics, at scale, through its remote access TrialTracker technology
platform, to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for the Company's pharmaceutical
clients.

 

 

More information is available on www.IXICO.com (http://www.IXICO.com) and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUKRWROVUORAR